CodeMap® Compliance Briefing: August 9, 2022
Since the 2018 Medicare Clinical Laboratory Fee Schedule, clinical laboratories have suffered significant cuts to Medicare reimbursement rates due to the Protecting Access to Medicare Act of 2014 (PAMA). In addition, since many private payers base their payment rates on Medicare, PAMA has indirectly impacted private payment rates as well. Hopefully, laboratories may soon see some relief from these downward pressures on revenue. Today, our friends at Laboratory Economics discuss recent legislation and ongoing litigation that may reduce the negative impacts of PAMA felt by clinical laboratories over recent years. As always, please send your comments, suggestions, and questions to us via email.
Sorry, access to this content requires a current subscription.
Click here for publications catalog.
CPT copyright 2021 American Medical Association. All rights reserved.
* The responsibility for the content of any "National Correct Coding Policy" included in this product is with the Centers for Medicare and Medicaid
Services and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable to or related
to any use, nonuse, or interpretation of information contained in this product.